Erratum: One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: Results from 2 multicenter randomized, controlled trials (Pediatrics (June 2007) 119 (e361-e1370) doi 10.1542/peds.2006-0149);One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: Results from 2 multicenter randomized, controlled trials

Pediatrics

Volumn 119, Issue 6, 2007, Pages 935-

  Moya, Fernando ^a   Sinha, Sunil ^b   Gadzinowski, Janusz ^c,d   D'Agostino, Ralph ^e   Segal, Robert ^f   Guardia, Carlos ^f   Mazela, Jan ^c,f   Liu, Genzhou ^f  

^a New Hanover Regional Medical Center   (United States)

^b JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^e USA   (United States)

^f Discovery Laboratories   (United States)

Author keywords

1 year outcome; Long term survival; Respiratory distress syndrome; Surfactant; Survival rate

Indexed keywords

BERACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; PORACTANT;

ARTICLE; CHILD HOSPITALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG DEVELOPMENT; MALE; MORTALITY; MULTICENTER STUDY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; NEWBORN; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; RESPIRATORY TRACT DISEASE; SURVIVAL; TREATMENT OUTCOME;

EID: 34249899380     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2007-2435     Document Type: Erratum

References (39)

1. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2001;(2):CD000144
2. Notter RH, Wang Z, Egan EA, Holm BA. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids. 2002;114:21-34
3. Curstedt T, Jörnvall H, Robertson B, Bergman T, Berggren P. Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant: characterization and biophysical activity. Eur J Biochem. 1987;168:255-262
4. Clark JC, Wert SE, Bachurski CJ, et al. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc Natl Acad Sci USA. 1995;92:7794-7798
5. Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest. 1994;93:1860-1863
6. Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA. Brief report: a mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001;344:573-579
7. Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science. 1991;254:566-568
8. Andersson S, Kheiter A, Merritt TA. Oxidative inactivation of surfactants. Lung. 1999;177:179-189
9. Revak SD, Merritt TA, Cochrane CG, et al. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res. 1996;39:715-724
10. 4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153:404-410
11. Moya FR, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. 2005;115:1018-1029
12. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very preterm infants at high risk for respiratory distress syndrome. Pediatrics. 2005;115:1030-1038
13. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med. 2003;22:169-186
14. International conference on harmonisation; guidance on statistical principles for clinical trials: availability - FDA. Notice. Fed Regist. 1998:63:49583-49598
15. Cupples LA, Gagnon DR, Ramaswamy R, D'Agostino RB. Age-adjusted survival curves with application in the Framingham study. Stat Med. 1995;14:1731-1744
16. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 1997;(4):CD000511
17. Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants [Cochrane review]. In: The Cochrane Library. Issue 2. Chichester, United Kingdom: John Wiley & Sons, Ltd; 2004
18. Horbar JD, Wright LL, Soll RF, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr. 1993;123:757-766
19. Vermont-Oxford Network. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics. 1996;97:1-6
20. Alvarado M, Hingre R, Hakason D, Gross S. Clinical trial of Survanta versus Exosurf in infants <1500 g with respiratory distress syndrome [abstract]. Pediatr Res. 1993;33:314A
21. da Costa DE, Pai MG, Al Khusaiby SM. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. Pediatr Pulmonol. 1999;27:312-317
22. Modanlou HD, Beharry K, Padilla G, Norris K, Safvati S, Aranda JV. Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. J Perinatol. 1997;17:455-460
23. Pearlman SA, Leef KH, Stefano JL, et al. A randomized trial comparing Exosurf versus Survanta in the treatment of neonatal RDS [abstract]. Pediatr Res. 1993;33:340A
24. Sehgal SS, Ewing CK, Richards T, Taeusch HW. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Natl Med Assoc. 1994;86:46-52
25. Hudak ML, Farrell EE, Rosenberg AA, et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr. 1996;128:396-406
26. Hudak ML, Martin DJ, Egan EA, et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics. 1997;100:39-50
27. Kukkonen AK, Virtanen M, Järvenpää AL, Pokela ML, Ikonen S, Fellman V. Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant? Acta Paediatr. 2000;89:556-561
28. Ainsworth SB, Beresford MW, Milligan DWA, et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial [published correction appears in Lancet. 2000;356:600]. Lancet. 2000;355:1387-1392
29. Horbar JD, Badger GJ, Carpenter JH, et al. Trends in mortality and morbidity for very low birth weight infants, 1991-1999. Pediatrics. 2002;110:143-151
30. Bloom BT, Kattwinkel J, Hall RT, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics. 1997;100:31-38
31. Bloom BT, Clark RH; Infasurf Survanta Clinical Trial Group. Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics. 2005;116:392-399
32. Speer CP, Gefeller O, Groneck P, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1995;72:F8-F13
33. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol. 2004;21:109-119
34. Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr. 2005;94:779-784
35. Halliday HL. History of surfactant from 1980. Biol Neonate. 2005;87:317-322
36. Sinn JK, Ward MC, Henderson-Smart DJ. Developmental outcome of preterm infants after surfactant therapy: systematic review of randomized controlled trials. J Paediatr Child Health. 2002;38:597-600
37. Sell M, Cotton R, Hirata T, et al. One-year follow-up of 273 infants with birth weights of 700 to 1100 grams after prophylactic treatment of respiratory distress syndrome with synthetic surfactant or air placebo. American Exosurf Neonatal Study Group I. J Pediatr. 1995;126(5 pt 2):S20-S25
38. Survanta Multidose Study Group. Two-year follow-up of infants treated for neonatal respiratory distress syndrome with bovine surfactant. J Pediatr. 1994;124:962-967
39. Robertson B, Curstedt T, Tubman R, et al. A 2-year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Collaborative European Multicentre Study Group. Eur J Pediatr. 1992;151:372-376